Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center

Japanese Journal of Clinical Oncology

Volumn 41, Issue 5, 2011, Pages 647-655

  Kennoki, Takafumi ^a   Kondo, Tsunenori ^a   Kimata, Naoki ^a   Murakami, Jun ^a   Ishimori, Isamu ^a   Nakazawa, Hayakazu ^b   Hashimoto, Yasunobu ^a   Kobayashi, Hirohito ^a   Iizuka, Junpei ^a   Takagi, Toshio ^a   Yoshida, Kazuhiko ^a   Tanabe, Kazunari ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Adverse drug events; Hemodialysis; Pharmacokinetics; Renal cell carcinoma; Sorafenib

Indexed keywords

ERYTHROPOIETIN; SORAFENIB;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CEREBELLUM HEMORRHAGE; CLINICAL ARTICLE; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INFECTION; JAPANESE; KIDNEY CARCINOMA; KIDNEY FUNCTION; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROTOXICITY; OVERALL SURVIVAL; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PROGRESSION FREE SURVIVAL; SEPSIS; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; THROMBOCYTE; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEASIBILITY STUDIES; HEMATINICS; HEMOGLOBINS; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; RENAL DIALYSIS; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 79955829301     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr015     Document Type: Article

References (41)

1. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12.
2. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
4. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, et al. Randomized phase II trial of first-line treatment with sorafenibversus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1280-9.
5. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007;37:755-62.
6. Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M, et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 2010;40:194-202.
7. Kamada P, Dudek AZ. Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review. Cancer Invest 2010;28:501-4.
8. Veroux M, Corona D, Veroux P. Kidney transplantation: future challenges. Minerva Chir 2009;64:75-100.
9. Nakai S, Masakane I, Shigematsu T, Hamano T, Yamagata K, Watanabe Y, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2007). Ther Apher Dial 2009;13:457-504.
10. Ishikawa I. Present status of renal cell carcinoma in dialysis patients in Japan: questionnaire study in 2002. Nephron Clin Pract 2004;97:c11-6.
11. Farivar-Mohseni H, Perlmutter AE, Wilson S, Shingleton WB, Bigler SA, Fowler JE, Jr. Renal cell carcinoma and end stage renal disease. J Urol 2006;175:2018-20; discussion 21.
12. Ruppin S, Protzel C, Klebingat KJ, Hakenberg OW. Successful sorafenib treatment for metastatic renal cell carcinoma in a case withchronic renal failure. Eur Urol 2009;55:986-8; quiz 8.
13. Reckova M, Kakalejcik M, Beniak J. Treatment of hemodialyzedpatient with sunitinib. Ann Oncol 2009;20:392-3.
14. McIntyre CW. Effects of hemodialysis on cardiac function. Kidney Int2009;76:371-5.
15. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitorsunitinib. Lancet 2007;370:2011-9.
16. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006;12:7271-8.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response totreatment in solid tumors. European Organization for Research andTreatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
18. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-61.
19. Genton L, Hans D, Kyle UG, Pichard C. Dual-energy X-ray absorptiometry and body composition: differences between devices and comparison with reference methods. Nutrition 2002;18:66-70.
20. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinicalpharmacokinetics. Cancer Chemother Pharmacol 2006;57:685-92.
21. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advancedrenal cell carcinoma. J Clin Oncol 1999;17:2530-40.
22. Escudier B, Goupil MG, Massard C, Fizazi K. Sequential therapy inrenal cell carcinoma. Cancer 2009;115:2321-6.
23. Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinaseinhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 2008;99:1492-8.
24. Shinsako K, Mizuno T, Terada T, Watanabe J, Kamba T, Nakamura E, et al. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. Int J Clin Oncol 2010;15:512-4.
25. Hilger RA, Richly H, Grubert M, Kredtke S, Thyssen D, Eberhardt W, et al. Pharmacokinetics of sorafenib in patients with renal impairmentundergoing hemodialysis. Int J Clin Pharmacol Ther 2009;47:61-4.
26. Ferraris E, Di Cesare P, Lasagna A, Paglino C, Imarisio I, Porta C. Useof sorafenib in two metastatic renal cell cancer patients with end-stagerenal impairment undergoing replacement hemodialysis. Tumori 2009;95:542-4.
27. Rey PM, Villavicencio H. Sorafenib: tolerance in patients on chronichemodialysis: a single-center experience. Oncology 2008;74:245-6.
28. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995;47:884-90.
29. Agarwal R. Hypertension and survival in chronic hemodialysis patients-past lessons and future opportunities. Kidney Int 2005;67:1-13.
30. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, et al. Traditional cardiovascular disease risk factors in dialysis patientscompared with the general population: the CHOICE Study. J Am Soc N ephrol 2002;13:1918-27.
31. Rios DR, Carvalho MG, Lwaleed BA, Simoes e Silva AC, Borges KB, Dusse LM. Hemostatic changes in patients with end stage renal disease undergoing hemodialysis. Clin Chim Acta 2010;411:135-9.
32. Iseki K, Kohagura K. Anemia as a risk factor for chronic kidney disease. Kidney Int Suppl 2007;107:S4-9.
33. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009;20:807-15.
34. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009;10:967-74.
35. Parsa V, Heilbrun L, Smith D, Sethi A, Vaishampayan U. Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. Clin Genitourin Cancer 2009;7:E10-5.
36. Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009;27:1800-5.
37. Park CY. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis. Anticancer Drugs 2009;20:848-9.
38. Vickers MM, Heng DY, Hemmelgarn B, Eigl BJ. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009;7:E104-6.
39. Locatelli F, Pozzoni P, Tentori F, del Vecchio L. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant 2003;18:vii2-9.
40. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-37.
41. Izzedine H, Etienne-Grimaldi MC, Renee N, Vignot S, Milano G. Pharmacokinetics of sunitinib in hemodialysis. Ann Oncol 2009;20:190-2.